Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma

J Oncol Pharm Pract. 2019 Jul;25(5):1253-1257. doi: 10.1177/1078155218785967. Epub 2018 Jul 13.

Abstract

Multiple myeloma is a cancer of malignant plasma cells which stimulates osteoclasts and is associated with increased bone turnover and osteolysis. Bisphosphonates including zolendronic acid are used to prevent skeletal complications in patients with multiple myeloma. Orbital inflammation is a rare but serious complication following use of bisphosphonates. The diagnosis is made by excluding other possible causes in patients with myeloma and rapid initiation of therapy is required. Corticosteroids are the mainstay of therapy but the ideal treatment course has not been delineated. This report describes a case of this rare complication and provides a review of the literature.

Keywords: Zoledronic acid; bisphosphonate; multiple myeloma; orbital inflammation.

Publication types

  • Case Reports

MeSH terms

  • Bone Density Conservation Agents / adverse effects*
  • Diphosphonates / administration & dosage
  • Humans
  • Inflammation / chemically induced*
  • Male
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Orbital Diseases / chemically induced*
  • Zoledronic Acid / adverse effects*

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Zoledronic Acid